Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer
- 11 September 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Causes & Control
- Vol. 22 (12), 1639-1646
- https://doi.org/10.1007/s10552-011-9840-6
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Endometrial cancer associated with various forms of postmenopausal hormone therapy: A case control studyInternational Journal of Cancer, 2010
- Long-term Postmenopausal Hormone Therapy and Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- Use of Nonsteroidal Antiinflammatory Drugs and Risk of Endometrial CancerAmerican Journal of Epidemiology, 2009
- Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004International Journal of Cancer, 2009
- Menopausal Hormone Therapy and Risk of Epithelial Ovarian CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2007
- Endometrial cancer risk in estrogen users after switching to estrogen–progestin therapyCancer Causes & Control, 2007
- Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohortCancer, 2007
- Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2004
- Progestogen modification of endometrial histology in menopasual women.BMJ, 1978